Journal article
Phase II trial of vorinostat in advanced melanoma
Abstract
Introduction Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma. Methods We evaluated 32 patients with advanced primary cutaneous or ocular melanoma in a multi-institutional setting (PMH Phase II Consortium) with continuous daily oral vorinostat 400 mg. The primary endpoint was response rate by RECIST, with time to progression as a secondary endpoint. The study was designed to …
Authors
Haas NB; Quirt I; Hotte S; McWhirter E; Polintan R; Litwin S; Adams PD; McBryan T; Wang L; Martin LP
Journal
Investigational New Drugs, Vol. 32, No. 3, pp. 526–534
Publisher
Springer Nature
Publication Date
6 2014
DOI
10.1007/s10637-014-0066-9
ISSN
0167-6997
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic AgentsBiomarkersDisease-Free SurvivalFemaleFibroblast Growth FactorsHistone Deacetylase InhibitorsHistonesHumansHydroxamic AcidsMaleMelanomaMiddle AgedPolymorphism, Single NucleotideSkin NeoplasmsTumor Suppressor Protein p53Vascular Endothelial Growth Factor AVorinostatMelanoma, Cutaneous Malignant